Amarin Corp Plc (AMRN)

[dukesking]

Sleven, I agree with your assumption but I have one concern. I keep hearing statements that Hikma won’t infringe as long as they keep it under 10% of Vascepa sales. I don’t think that’s accurate. It has been estimated that less than 1 in 10 Vascepa scripts are for the Marine indication. I think that estimate is only relevant to the current and past sales of Vascepa before the CVD label and I think that’s a high number. Going forward, I believe that number will continue to shrink and eventually become 1 in 50 scripts or 2% of Vascepa sales. It won’t be 10% forever. It’s probably a moot point as I also believe Hikma will try to capture as much of the US CVD market as they can based on production restraints only. JT must address this with a lawsuit and or a true authorized generic Vascepa. Hikma is not generic Vascepa it’s generic Icosapent ethyl. IMO.